Slide 1: Q3 2012 Revenue
2012 Q3 CVENUC November 8, 2012 = cegedim
Slide 2: Safe Harbour Statement
Safe Harbour Statement This presentation contains forward-looking statements (made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995). 1995) By their nature, nature forward-looking statements involve risk and uncertainty. Forward-looking statements repre
Slide 3: Cegedim at a glance
=m cegedim ae Cegedim [Sej’.eh.deem] €911m 2011 Revenue 8,200 2011 Headcount 65% Recurring business Market Capitalization nO 20102; as of November 7, 2012 Makes healthcare business run simply and more efficiently
Slide 4: Following a second quarter during which economic conditions deteriorated
Following a second quarter during which economic conditions deteriorated in a number of developed countries and clients put off making decisions, L-f-L revenues returned to growth in the third quarter even though tough condi- tions persisted. wa cegedim
Slide 5: Key Figures
Key Figures | > Group | CRM & Strategic Data | Healthcare Professionals | Insurance & Services | Finance 5 This document should not be distributed without Cegedim authorization – Copyright 2012
Slide 6: Revenues up 1.4% L-f-L in Q3 2012
Revenues up 1 1.4% 4% L L-f-L f L in Q3 2012 ¼ Organic Drop in CRM and strategic t t i data d t more than offset by the strong growth in Healthcare professionals f i l andd Insurance and Services ¼ Structure Acquisition of ASP Line in July 2012 Disposal of Pharmapost in April 2012 ¼ Currency
Slide 7: CRM & Strategic Data
CRM & Strategic Data ¼ In mature markets Pharmaceutical companies’ continued belt- ti ht i tightening Impacting negatively the market research activity The number of CRM solution users is leveling off Stabilization of the situation in Italy and Spain Greece and Portugal remain mired in dif
Slide 8: Healthcare Professionals
Healthcare Professionals ¼ CHS (Cegedim Healthcare Software) Strong growth in Q3 after a stable H1 Strong growth in products for UK pharmacists following their swift adoption of the Electronic Prescription Service (EPS) Growth in sales to pharmacists in France Growth of US software for Docto
Slide 9: Insurance & Services
Insurance & Services ¼ Strong Growth Double-digit increase in revenue from online thi d third-party t payer managementt services i More than 30% growth in Q3 of SRH** in France Cegedim SRH continues to garner numerous commercial successes. ** Payroll and HR management outsourcing | Group | CRM
Slide 10: Revenue by Geography
Revenue by Geography Revenue by geography in Q3 2012 EMEA Sector France ex. France Americas APAC CRM & Strategic Data 32% 33% 25% 10% Healthcare Professionals 66% 29% 5% 0% Insurance & Services 100% 0% 0% 0% Cegedim 54% 26% 15% 5% Revenue by geography September 30, 2012 - YTD EMEA Sector France ex.
Slide 11: Effects of Currency
Effects of Currency Currency movements accounted for a 3.6% increase in revenue in the third quarter 2012 largely reflecting the strength of the USD, GBP and JPY against the Euro Currency Impact (EUR million) Q3 2012 YTD 2012 USD 3.2 7.6 GBP 20 2.0 43 4.3 JPY 0.3 0.8 Other 1.5 2.2 Total 70 7.0 14 9
Slide 12: Outlook
€ OUTLOOK
Slide 13: Various Sources of Growth
Various Sources of Growth ¼ CRM & Strategic Data New Pharmaceutical landscape More regulation Significant sales growth in emerging market Increasing g need for Information,, IT Solutions and Mobilityy ¼ Healthcare Professionals States willingness to improve the efficiency of healthcare sys
Slide 14: Cegedim has become a significant force in the digital field
Cegedim g has become a significant g force in the digital field ¼ In the CRM and strategic data sector with interactive CRM offerings across multiple mobile devices ¼ In the Healthcare professionals sector with software solutions and drug databases available on the web and tablet computers, and
Slide 15: Performance Improvement Plan: Update
Performance Improvement Plan: Update ¼ Last August, Cegedim decided to renew the Performance Improvement Plan it launched in November 2011 ¼ All the costs of the second plan will be recorded in H2 2012 ¼ A gross impact of more than €10 million is expected in 2013 ¼ Along with revenue growth, the PIP
Slide 16: Outlook
Outlook(1) ¼ Economic environment will remain tough in Q4 2012 ¼ The Performance Improvement Program is extended into the H2 2012 ¼ No N plan l tto make k ffurther th acquisitions i iti b by th the end d off th the year ¼ 2012 Outlook(1) Despite a satisfactory performance in Q3 2012, the Group pre
Slide 17: Financial Targets
Financial Targets ¼ Restore Profitability, Restore profitability to 2009 level ¼ Increase cash-flow generation ¼ Focus on debt reduction Reach a leverage ratio of 2.0x in mid term ¼ Priority to organic growth No acquisition in H2 2012 and 2013 | > Group | CRM & Strategic Data | Healthcare Prof
Slide 18: 2013 Finance agenda
2013 Finance agenda A month earlier than last year | Group | CRM & Strategic Data | Healthcare Professionals | Insurance & Services | > Finance 18 This document should not be distributed without Cegedim authorization – Copyright 2012
Slide 19: 3rd Investor Summit
3rd Investor Summit Tuesday 15 January 2013 SAVE THE DATE
Slide 20: Appendix
Appendix Hard copy only
Slide 21: What's Great about Cegedim?
What’s Great about Cegedim? All player in the healthcare world Life sciences 200k+ users 78k+pharmacits a 115k+physicians 30k+paramedics 30 millions people covered Supporting clients = in 94 countries *HCP : Healthcare Professional Strong Portfolio Dedicated healthcare sector Worldwide database of H
Slide 22: A Resilient Core Business and a Solid Financial Profile
A Resilient Core Business and a Solid Financial Profile ¼ Steady Business Profile Recurring revenues relying mostly on a subscription based model (≈65% of revenue) Diversification (business (business, geography geography, customer) Critical size with strong market share in all business segment
Slide 23: Competitive Strengths
Competitive Strengths ¼ Leading market positions in each of our divisions ¼ High barriers to entry ¼ Strong customer base with recurring revenue ¼ Portfolio of innovative and integrated products and services ¼ Shareholder support pp ¼ Strong g and experienced p senior management g team and qualified
Slide 24: Keep in Touch
Keep in Touch | Group | CRM & Strategic Data | Healthcare Professionals | Insurance & Services | > Finance 24 This document should not be distributed without Cegedim authorization – Copyright 2012
Slide 25: We welcome your questions and comments
=i, cegedim We welcome your questions and comments Jan Eryk UMIASTOWSKI Chief Investment Officer Head of Investor Relations janeryk.umiastowski@cegedim.com www.cegedim.com/finance TEL: +33 (Q) 1 49 09 33 36